Pharma BD Deal Intelligence
The largest pharma acquisition of its era—$68B financed with $22.5B in debt—was a bet that Wyeth's vaccine franchise could cushion Pfizer through the Lipitor patent cliff. Prevnar 13 delivered spectacularly ($40B+ cumulative), but diversification only partially materialized.
Wyeth brought Prevnar, biologics platform, and $4B synergies but stock underperformed
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer Inc., announced Monday it is acquiring rival company Wyeth for about $68 billion, in the largest pharmaceutical sector takeover since 2000.
Pfizer Inc today announced the completion of its acquisition of Wyeth, creating the world's premier biopharmaceutical company.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Pfizer acquired Wyeth for approximately $68 billion in a cash-and-stock transaction, gaining a leading biologics portfolio including Prevnar and Enbrel, diversifying beyond small molecules into vaccines, biologics, and consumer health.
Wyeth brought Prevnar, biologics platform, and $4B synergies but stock underperformed
Assessment window: 5yr post-close.
17M US cases/yr · $11.0B US Antidepressant Market (2009)
Major depressive disorder affected an estimated 21.0 million US adults (8.3%) in 2021, with higher prevalence in women (10.3%) than men (6.2%) and peak burden in ages 18-25 (18.6%). MDD is defined by at least two weeks of depressed mood or anhedonia plus sleep, appetite, energy, concentration, or self-worth disturbances. About 14.5 million adults experienced severe functional impairment. Only ~61% of affected adults received treatment in the past year.
By 2009, the antidepressant market was highly genericized with SSRIs (Prozac, Zoloft, Paxil) all off-patent. Effexor XR was losing exclusivity, making Pristiq critical for franchise continuity. Competitors included Lilly's Cymbalta (duloxetine), Forest's Lexapro (escitalopram), and emerging atypical antipsychotic adjunctive therapies.
1.3M US cases/yr · $8.5B US RA Biologics Market (2009)
Rheumatoid arthritis is a chronic autoimmune disease affecting ~1.3M US adults, with women affected two to three times more often than men. Immune cells inflame the synovium, which thickens and invades cartilage and bone, producing symmetric polyarticular pain, swelling, warmth, and progressive erosive joint damage. Untreated disease drives functional disability, cardiovascular morbidity, and premature mortality. Presentation ranges from mild oligoarticular inflammation to aggressive polyarticular disease with extra-articular manifestations.
The TNF inhibitor market in 2009 was a three-way race: Enbrel (Wyeth/Amgen), Humira (Abbott), and Remicade (J&J/Merck). Humira was gaining share with its broader label. Emerging JAK inhibitors (tofacitinib) and anti-IL-6 agents (tocilizumab, approved 2010) threatened to erode TNF dominance. Biosimilar competition was still years away but looming.
900K US cases/yr · $3.2B US Pneumococcal Vaccine Market (2009)
Pneumococcal disease is a serious bacterial infection caused by Streptococcus pneumoniae, presenting as community-acquired pneumonia, meningitis, bacteremia, acute otitis media, and sinusitis. The pathogen colonizes the nasopharynx and invades via direct or hematogenous spread. Burden concentrates in children under 5 and adults 65+, with invasive disease carrying substantial case-fatality, particularly in meningitis and bacteremic pneumonia. Reinfection occurs because natural infection does not confer durable cross-serotype immunity.
In 2009, Wyeth's Prevnar dominated the pediatric pneumococcal vaccine market with >90% share. Merck's Pneumovax 23 (polysaccharide) served the adult market but lacked conjugate technology. GSK was developing Synflorix (10-valent) for emerging markets. Prevnar 13, in late-stage development at deal close, would extend coverage to 13 serotypes and open the adult market.
Rapamune (sirolimus) competes within solid-organ transplant maintenance immunosuppression, a multi-drug cocktail market where most backbone therapies are generic and branded share is limited. The calcineurin inhibitor (CNI) class is the standard-of-care backbone and the principal competitor category: tacrolimus (Prograf and generics; extended-release formulations Astagraf XL and Envarsus XR, Astellas/Veloxis) and cyclosporine (Neoral/Sandimmune and generics, Novartis) anchor most regimens. Within the mTOR inhibitor class itself, Rapamune's direct in-class competitor is Zortress/Certican (everolimus, Novartis), approved for kidney and liver transplant rejection prophylaxis; generic sirolimus from multiple manufacturers is also widely available. Antimetabolite adjuncts include CellCept (mycophenolate mofetil, Genentech/Roche) and Myfortic (mycophenolate sodium, Novartis), both genericized. The costimulation blocker class is represented by Nulojix (belatacept, BMS), a selective T-cell costimulation blocker approved for kidney transplant as a CNI-sparing alternative. Induction agents include Thymoglobulin (anti-thymocyte globulin, Sanofi) and Simulect (basiliximab, Novartis, IL-2 receptor antagonist). Commercial-lead read: Rapamune is a niche maintenance agent used selectively for CNI-sparing or malignancy-reduction strategies; generic sirolimus and everolimus together have commoditized the mTOR class, and the commercial franchise is durable only through adherence/formulation differentiation.
Pfizer and Wyeth announced a definitive merger agreement at $50.19 per share, totaling approximately $68 billion in cash and stock, financed by a $22.5 billion bank consortium.
The Federal Trade Commission accepted a Consent Order clearing the proposed $68 billion Pfizer acquisition of Wyeth, requiring limited divestitures to address overlapping product lines.
Pfizer completed its $68 billion acquisition of Wyeth, creating the world premier biopharmaceutical company with combined revenues exceeding $50 billion and a leading biologics portfolio.
Pfizer revenue increased 36% in 2010 to $67.8 billion compared to $50 billion in 2009, driven by inclusion of legacy Wyeth products for a full year adding $18.1 billion in revenue.
Pfizer achieved its target of approximately $4 billion in annual cost savings from the Wyeth integration by the third year after closing, across SG&A, R&D, and manufacturing functions.
Wyeth brought Pfizer Prevnar, Enbrel rights, and a world-class biologics manufacturing platform that remains central to its capabilities, though Pfizer stock underperformed peers for years.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Wyeth (this deal) | 2009 | $68.0B | 86 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
| Pfizer Inc. / Seagen Inc. | 2023 | $43.0B | 77 |
← Browse all deals · How we score deals
More: 2009 deals · Pfizer Inc. deals · Cardiovascular deals